Combined Analysis of Audiologic Performance and the Plasma Biomarker Stromal Cell-Derived Factor 1a in Type 2 Diabetic Patients

Loader, Benjamin; Stokić, Dejan; Riedl, Michaela; Hickmann, Sonja; Katzinger, Michaela; Willinger, Ulrike; Luger, Anton; Thurner, Stefan; Wick, Nikolaus

doi:10.1097/mao.0b013e318172cf89

Cited by 11 publications

(10 citation statements)

References 19 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, Loader et al . reported higher plasma stromal cell‐derived factor 1a (SDF‐1a) concentrations, a biomarker of microangiopathy, in people with Type 2 diabetes with higher PTA thresholds compared with people without diabetes .…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, the associated hypertension intensifies diabetic end-organ damage in the cochlea, with a synergistic effect on hair cell loss [16,28]. Finally, Loader et al [30] reported higher plasma stromal cell-derived factor 1a (SDF-1a) concentrations, a biomarker of microan-giopathy, in people with Type 2 diabetes with higher PTA thresholds compared with people without diabetes [30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cochlear, auditory brainstem responses in Type 1 diabetes: relationship with metabolic variables and diabetic complications

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cochlear, auditory brainstem responses in Type 1 diabetes: relationship with metabolic variables and diabetic complications

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This inability of diabetic EPCs to respond to the CXCL12 may contribute to aberrant tissue vascularization and endothelial repair in diabetic patients [52]. Loader et al reported significantly higher plasma CXCL12 concentrations in T2D patients (who also presented with higher pure-tone audiometry thresholds) compared to nondiabetic subjects [53]. Furthermore, an association was observed between CXCL12 and audiometric performance, body mass index, and duration of diabetes.…”

Section: Status Of Cxcl12 In T2dmentioning

confidence: 94%

“…Furthermore, an association was observed between CXCL12 and audiometric performance, body mass index, and duration of diabetes. They hypothesized that diabetic microangiopathy and CXCL12 as one of its biomarkers should be considered as potential pathogenetic factors for altered hearing potency of diabetics [53]. Ferraro et al reported that in mouse models of both T1D and T2D, the release of hematopoietic stem progenitor cells (HSPCs) from the bone marrow after granulocyte colony-stimulating factor (G-CSF) treatment was impaired.…”

Section: Status Of Cxcl12 In T2dmentioning

confidence: 99%

Significance of CXCL12 in Type 2 Diabetes Mellitus and Its Associated Complications

Karimabad

Hassanshahi

2014

Inflammation

View full text Add to dashboard Cite

Immune responses are extensively accepted as primitive etiological leading causes involved in immune system diseases. It is now well established that chemokines as the main arms of the immune system play critical roles in the regulation of immune responses in the pathogenesis of different diseases. Several environmental and genetic elements of the immune system are also believed to potentially affect both the onsets of immunological diseases. The stromal cell-derived factor-1 alpha (SDF-1α) which in new nomenclature is nominated as C-X-C motif ligand 12 (CXCL12) is involved in the development and progression of immune responses. The CXCL12 is an extensively active chemokine that serves as a recruiter for migration and trafficking of leukocytes and hematopoietic progenitor cells. Patients suffering type 2 diabetes (T2D) that ascribe heterozygous SDF-1 3'A genotype (801G/A in the 3' untranslated region) have increased insulin-dependent mobilization of adult progenitor cells, which are known to participate in angiogenesis and vascular repair. Conversely, homing of progenitor cells contributes to the diabetes vascular complications. Because carriers of the SDF-1 3'A genotype show increased levels of the CXCL12 messenger RNA (mRNA) in their peripheral blood mononuclear cells. Genetic variations of CXCL12 gene might affect trafficking of inflammatory cells or defected precursors and hence induced tendency to diabetic complications. The SDF-1 3'A genetic variation of CXCL12 influences the development of late vascular diabetic complications, and previous studies reported that this genetic variation regulates the expression of CXCL12. Therefore, the main goal of the present study was to collect the most recent reports regarding the relation between serum concentrations and SDF-1 3'A genetic variation of CXCL12 in T2D.

show abstract

“…An interesting route in the examination of diabetes and hearing loss was reported by Loader et al 22 They compared hearing thresholds as well as blood samples in 18 diabetic subjects (ages 34 to 75 years) and 18 nondiabetic age-matched controls to assess whether levels of a biomarker for microangiopathy, stromal cell-derived factor 1a (SDF-1a), was correlated to pure-tone hearing thresholds. No significant neuropathic complications, nephropathy, or retinopathy was noted in the diabetic subjects.…”

Section: Auditory Function and Diabetesmentioning

confidence: 99%

Exploring the Association of Hearing Loss with Diabetes Mellitus: A Critical Review

Wolfe¹,

Honaker

Decker³

2011

Semin Hear

View full text Add to dashboard Cite

The prevalence of diabetes mellitus is quickly growing in the U.S. population, and among these individuals, many suffer from auditory impairment of increased severity compared with healthy individuals without diabetes. Clinical implications of diabetes mellitus and its affect on the auditory system have been widely recognized in the literature. This article reviews current evidence detailing the association between hearing loss and diabetes mellitus. Traditional and novel methods used in research of this association will be discussed, and descriptions for general audiological precautions for diabetic patients will be outlined. Although controversy exists in the literature, knowledge of the possible audiological aspects of the diabetic individual is paramount and exceedingly relevant to audiological practice as this population continues to increase. Continued research will provide further insight for which specific audiological management of these patients may be established.Learning Outcomes: As a result of this activity, the participant will be able to: (1) list three audiological tests that may present with abnormal findings and (2) describe the findings often associated with the above tests.Diabetes mellitus is quickly becoming an epidemic, affecting 25.8 million people in 2010 1 and a projected 30 million people by 2030. 2 Diabetes mellitus is a metabolic disease characterized by autoimmune-related insulin deficiency (type 1) and the improper use of insulin by body cells (type 2). Type 1 is often referred to as insulin-dependent diabetes (IDDM) and affects $5 to 10% of the diabetic population. 3 Type 2 is referred to as non-insulin-dependent

show abstract

Combined Analysis of Audiologic Performance and the Plasma Biomarker Stromal Cell-Derived Factor 1a in Type 2 Diabetic Patients

Abstract: We hypothesize that diabetic microangiopathy and its biomarker SDF-1a should be considered as potential pathogenetic factors for altered diabetic hearing, warranting further investigation.

Cited by 11 publications

References 19 publications

Cochlear, auditory brainstem responses in Type 1 diabetes: relationship with metabolic variables and diabetic complications

Cochlear, auditory brainstem responses in Type 1 diabetes: relationship with metabolic variables and diabetic complications

Significance of CXCL12 in Type 2 Diabetes Mellitus and Its Associated Complications

Exploring the Association of Hearing Loss with Diabetes Mellitus: A Critical Review

Contact Info

Product

Resources

About